Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top London based Founder operating in the Biotechnology space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Valentina Milanova
Founder and CEO of Daye
Valentina previously worked with Techstars as a Business Development Associate. She is currently looking after the AI portfolio at Founders Factory – launching 200 businesses in the next five years! Before entering the startup and VC worlds, Valentina studied law and worked as a technology correspondent for large international publications.
Follow Valentina Milanova:
About Daye: Daye creates category-defining products and services that set a new standard for medical research and scientific innovation.
_______
Sara Murray
Founder & Chief Executive Officer of Buddi
Sara Murray (M.A. Oxon) is a serial entrepreneur. She founded Ninah Consulting, which uses proprietary software to advise clients, including GSK and Coca-Cola, on marketing effectiveness, and sold it to Publicis Groupe. In 1999, Sara founded Inspop, which owns the brand Confused.com. She built and sold the online company to the Admiral Group. She was a non-executive Director of Schering Health Care and a founding board member of Seedcamp. Sara won the Entrepreneur of the Year Award 2009 and sits on the Technology Strategy Board Governing Board. Sara was awarded an OBE for services to Entrepreneurship and Innovation in the Queen’s Birthday Honours 2012 and is a qualified helicopter pilot.
Follow Sara Murray:
About Buddi, Confused.com: Buddi is an innovative, high-growth and british technology company that develops location and health monitoring technologies.
Siro Perez
Co-Founder & CEO of Molecular Warehouse
Follow Siro Perez:
About IP Group, Kira Biotech, Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
Nikita Alexandrov
Co-Founder of Molecular Warehouse
Nikita brings advanced expertise in instrumentation and high throughput research techniques. Prior to MW, he founded Permanetix Corporation, developing technology in the field of Fusion energy. Previously, he was the first employee in the aerospace materials testing start-up XEEL Corp, where he developed tools and techniques for high energy testing of space flight hardware for NASA. Nikita graduated from Auburn University (USA) in 2012, with a degree in chemistry, focusing on analytical chemistry, where he received his own lab to conduct chemical plasma reactor research and development. Nikita has an MBA from the University of Alabama (USA).
Follow Nikita Alexandrov:
About Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
Benjamina Bollag
Founder & CEO of HigherSteaks
Benjamina is the CEO of London-based food tech start-up Higher Steaks, which she founded in 2017. Previously, Benjamina co-founded a London-based B2B electronics company selling to FTSE500 companies. Benjamina has also worked at Israeli 3D printing company, Stratasys, at the digital marketing division of PepsiCo’s joint venture with Strauss and was the lead developer an ed-tech startup. Benjamina holds a Master of Chemical Engineering from the Imperial College, where she completed a project focusing on the design of a peptide plant, conducting a lab-based research on synthesis and liquid exfoliation of graphitic carbon nitride
Follow Benjamina Bollag:
About HigherSteaks, Zestful: HigherSteaks is about providing with that juicy, tender, and delicious meat they love but without harming their health, planet, and animals.
George Goldsmith
Executive Chairman, Chief Executive Officer & Co-Founder of COMPASS Pathways
George is a serial entrepreneur with significant experience in pharmaceutical regulation. George’s early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science.His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks’ Non-Executive Chairman. George also serves on the board of directors for AnaBios, a company redefining drug discovery. He and his wife, Ekaterina Malievskaia MD, live in London.
Follow George Goldsmith:
About COMPASS Pathways: Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
Ekaterina Malievskaia
Chief Innovation Officer & Co-Founder of COMPASS Pathways
Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia. After her Internal Medicine residency training, she completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York. After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member.
Follow Ekaterina Malievskaia:
About COMPASS Pathways: Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
Gabriella Santosa
Co-Founder and CSO of Puraffinity
Follow Gabriella Santosa:
About Puraffinity: Puraffinity develops precision materials to target chemicals, with an initial focus on PFAS in water
Henrik Hagemann
CEO and Co-Founder of Puraffinity
Follow Henrik Hagemann:
About Puraffinity, Tech London Advocates: Puraffinity develops precision materials to target chemicals, with an initial focus on PFAS in water
Houman Ashrafian
Managing Partner & Founder of SV Health Investors
Houman Ashrafian is the Managing Partner at SV Health Investors.
Follow Houman Ashrafian:
About Catamaran Bio, Cellinta, Enara Bio, Karus Therapeutics, Sitryx Therapeutics, SV Health Investors, Zarodex Therapeutics: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Stephan Tual
Founder, CEO of 3 Billion Pairs Genetic
Stephan Tual is the Founder & CEO at 3 Billion Pairs Genetics Ltd. & he attended Institut Franco-Américain de Management in 1995.
Follow Stephan Tual:
About 3 Billion Pairs Genetic: 3 Billion Pairs Genetic is a biotechnology based company.
Maria Chatzou Dunford
CEO and Co-Founder of Lifebit
Dr. Maria Chatzou, CEO of Lifebit, is a biotech innovator and a proud geek, expert in bioinformatics, medical informatics and high performance computing. She is also a passionate entrepreneur and has founded two companies, Innovation Forum Barcelona and Techstars-backed Lifebit. Prior to Lifebit, she was a researcher at the Centre for Genomic Regulation, in Barcelona, where she was designing and deploying tools and methods that facilitate the analysis of Big Biomedical Data, allow for biological discoveries, and promote personalised medicine. She was part of the developing team of Nextflow, a programming framework that is revolutionising the computational analysis of genomic data and setting the foundations for personalised medicine computational analyses. Maria is also a frequent industry speaker and has spoken in many international conferences on the subjects of docker containers, genomics workflows, the computational challenges of personalised medicine, AI and HPC in genomics, women in leadership, entrepreneurship, science ventures, among many other topics.
Follow Maria Chatzou Dunford:
About Lifebit: Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Pablo Prieto Barja
CTO and Co-Founder of Lifebit
Follow Pablo Prieto Barja:
About Lifebit: Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Arthur Kay
Founder of bio-bean
Arthur Kay is an award-winning designer and entrepreneur, the Co-Founder and CEO of bio-bean, an award-winning green energy company that recycles waste coffee grounds into advanced biofuels. Arthur came up with the idea for bio-bean whilst studying architecture at The Bartlett, UCL, and in two years has raised several million in financing, built the world’s first coffee waste recycling factory and a team of twenty. He currently holds positions on a number of boards associated with social enterprise and green entrepreneurship and is a Fellow of WIRED, the RSA and IoD. In 2013, Shell named him ‘the UK’s most Innovative Entrepreneur,’ he was appointed as a ‘London Leader’ by Mayor Boris Johnson, in 2014 he became one of NESTA’s ‘New Radicals’ and was named ’25 under 25 most influential Londoners’ by the Evening Standard. He was named the youngest ever Guardian Sustainable Business Leader of the Year in 2015.
Follow Arthur Kay:
About bio-bean, Skyroom, UCL, United Nations Global Compact: bio-bean is a U.K.-based green company that offers its users with processes of recycling and waste management solutions.
Gregg Sando
Founder & former Chief Executive Officer of Kuur Therapeutics
Gregg Sando is the founder and CEO of Cell Medica. After a career in investment banking based both in London and New York, he completed his Immunology MSc degree at the medical school of Imperial College. Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in cooperation with a small group of the leading clinicians and immunologists who were pioneering this new mode of medical treatment. (B.A. Biochemistry, Harvard University; M.B.A. University of Chicago; MSc Immunology, Imperial College London).
Follow Gregg Sando:
About Kuur Therapeutics: Kuur Therapeutics is committed to transforming the lives of patients with cancer & is leading the development cell therapies.
Jonathan Sieff
Co-Founder of Polymateria
Jonathan Sieff is the Co-Founder of Polymateria.
Follow Jonathan Sieff:
About Polymateria: Polymateria is a London-based startup advancing science to help nature deal with plastic pollution.
Lee Davy-Martin
Co-Founder of Polymateria
Lee Davy-Martin is the Co-Founder of Polymateria.
Follow Lee Davy-Martin:
About Polymateria: Polymateria is a London-based startup advancing science to help nature deal with plastic pollution.
Michael Brennan
Co Founder & Non-Executive Director of BenevolentAI
Mr. Michael Brennan co-founded BenevolentAI Limited in 2013 and serves as its Head of Corporate Development. Mr. Brennan co-founded Novum Securities in 2006 and served as it Chief Executive Officer. In 2009, Mr. Brennan joined Proximagen Group plc, as Head of Corporate Development, where he was focused on fund raising, corporate transactions and business development. Mr. Brennan has over 14 years of equity capital markets experience in the City focusing on the small and mid cap market. He is a Senior corporate finance executive with over 15 years City based capital markets experience. The majority of his time was spent with Evolution Securities where he served as a Director in their corporate finance department and has significant transactional experience including M&A and takeover work. He has been a Non-Executive Director at Litebulb Group Limited since September 13, 2013.
Follow Michael Brennan:
About BenevolentAI, SimplyPayMe: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Ivan Griffin
COO & Co-Founder of BenevolentAI
Ivan joined NESTA in March 2009. He makes and manages investments in the Healthcare sector. Prior to joining NESTA Ivan spent four years at IP Group where he was predominantly focused on healthcare and life science businesses. At IP Group his role encompassed all aspects of technology commercialisation, including identification of investment opportunities, spin-out company formation, business and corporate development as well as private and public equity financings and trade sales. Before joining IP Group Ivan spent two years at Oxford Technology Venture Capital Trust, and a year in post-doctoral research where he published several scientific papers.
Follow Ivan Griffin:
About BenevolentAI: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Brent Gutekunst
Chief Development Officer & Founder of BenevolentAI
Mr. Brent Gutekunst co-founded BenevolentAI Limited in 2013 and also serves as its Chief Development Officer. Mr. Gutekunst is the founder of Stratified Medical, Inc. Previously, he founded TouchDx in 2009. Prior to TouchDx, he founded E-Auction. He also founded Collectors Universe and after merging with leading firms in the collectibles industry completed a successful IPO in collectibles.
Follow Brent Gutekunst:
About BenevolentAI: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Ken Mulvany
Founder & Board Director of BenevolentAI
Mr. Ken Mulvany is a serial entrepreneur and investor with more than 20 years of business leadership experience. He is the Founder and Chairman of BenevolentAI, a $2bn machine intelligence company with end-to-end drug development capabilities. Mr. Mulvany was previously Founder and CEO of Proximagen, a leading biotech company developing medicines for central nervous system disorders, which he sold in 2012. Mulvany sits on several advisory boards including the advisory panel to the UK Government on Artificial Intelligence and the Advisory Board for Oxford Sciences Innovations. He is a member of the All-Party Parliamentary Group on Artificial Intelligence, and formerly, the Chairman of the Trustees of the Cure Parkinson’s Trust. Mr. Mulvany is a world champion sailor and competed in the 1992 America’s Cup.
Follow Ken Mulvany:
About BenevolentAI: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Aris Papageorghiou
Co-Founder & CMO of Intelligent Ultrasound
Aris Papageorghiou is the Professor of Fetal Medicine at University of Oxford.
Follow Aris Papageorghiou:
About Intelligent Ultrasound, Royal College of Obstetricians and Gynaecologists, St Georges University Hospitals NHS Foundation Trust, Ultrasound Diagnostic Services, University of Oxford: Intelligent Ultrasound develops software that improves the quality, reliability, and diagnostic power of medical ultrasound.
Amit Nathwani
Founder & Chief Scientific Officer of Freeline
Amit is renowned for his pioneering work on gene therapy for haemophilia B, and was first to show successful correction of bleeding diathesis in patients with severe haemophilia B. Amit is the Director of the Katharine Dormandy Haemophilia Centre at the Royal Free Hospital, and a Senior NIHR Investigator. He is also Professor of Haematology at UCL. He graduated in Medicine from the University of Aberdeen in 1984. In 1997 he moved to St. Jude Children’s Research Hospital, Memphis, USA, to work with Dr Arthur Nienhuis on adeno-associated virus mediated gene transfer. Here he started his pioneering work on gene therapy for haemophilia B. In 2001 he returned to University College London as a Senior Lecturer in Haematology and a Consultant to the National Blood Services in the UK. He was the first to show successful correction of bleeding diathesis in patients with severe haemophilia B, using a distinct gene transfer approach developed in collaboration with Dr’s Davidoff and Nienhuis at St Jude Children’s Research Hospital.
Follow Amit Nathwani:
About Freeline: Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
Aron Rachamim
Founder & CEO of Senzo
Aron Rachamim is committed to changing the world by putting healthcare information into everyone’s hands. A serial entrepreneur, scientist, and experienced leader, Aron aims to apply pioneering technologies to improve people’s quality of life. His expertise and passion for the science of microfluidics builds on his background in life sciences, physics, and engineering. His company Orphidia intends to transform the world of medical diagnostics. Aron launched Orphidia in 2013 to provide affordable, point-of-care diagnostics that allow everyone to know their health. Orphidia has advanced the state-of-the-art with microfluidic-based medical diagnostics that are minimally invasive, replacing venous blood draws from a phlebotomist with a simple fingerstick that anyone can perform. Aron is a serial entrepreneur, whose background combines a PhD from the University of Cambridge and a focus on microfluidics and biotechnology with strong experience in professional management. At Protein Logic, a spin-out from Cambridge University that raised more than £3 million in initial funding to develop proprietary biomarker technology for the diagnosis and prediction of diseases, he served as COO. At WiseMed, where he was Co-founder, his team developed crowdsourced medical diagnostic technology as an affordable solution for improving healthcare in the developing world. Now, at Orphidia, Aron is providing the vision and leadership that will usher in the next generation of medical diagnostics, empowering everyone to know their health.
Follow Aron Rachamim:
About Senzo: Senzo is a deep-tech bio-med company developing testing products and IP.
Abdullah Sabyah
Founder and CEO of Rightangled
A scientist-entrepreneur and a healthcare professional, also a member of the British Heart Foundation Alliance, a member of the Clinical Pharmacogenomics Implementation Consortium in the US, and the inventor of a patent pending-technology for nucleic acid testing on a lateral flow assay (the patent is for a technology to detect DNA sequences in real-time).
Follow Abdullah Sabyah:
About Rightangled: Medtech specialised in Genetics, Blood and infection testing. Service is delivers through a platform that connects users with specialists.
Mario Alberto Accardi
CEO and Co-Founder of Orexia
Life sciences executive and investor focused on starting, funding and running companies in the life sciences. Over a decade experience in the industry spanning fundamental research, venture capital and operational roles. I am now CEO and Co-Founder of Orexia and Inexia, two biotech companies founded with VC investor Medicxi and Sosei Heptares. I am also CEO and Co-Founder and inventor behind Orthonika, a medtech spin-out from Imperial College London.
Follow Mario Alberto Accardi:
About Orexia, Orthonika: Orexia aims to develop orally administered orexin positive modulators for the treatment of neurological diseases.
Andrea Spezzi
Chief Medical Officer & Co-Founder of Orchard Therapeutics
Andrea is a co-founder of Orchard Therapeutics and brings to the company extensive experience and expertise in the development and execution of all aspects of clinical development and particularly in paediatric rare diseases. Prior to joining Orchard Therapeutics, Andrea served as VP and Medicine Development Leader at GSK Rare Diseases Unit. Previous to joining the GSK Rare Diseases Unit, Andrea was Senior Medical Director at the Immune Inflammation Discovery Performance Unit. Before GSK, Andrea was Global Medical Director R&D at Takeda in the metabolic and cardiovascular area and in charge of the paediatric developments for Takeda Europe R&D. Before that, she worked as Research Physician at Hammersmith Medicines Research. Before moving to the pharmaceutical industry Andrea practiced as a paediatrician for 12 years in Argentina, Spain and UK. Andrea obtained her medical degree from the University of Buenos Aires (UBA) and completed residency in paediatrics and post graduate training in paediatric immunology at the Dr Elizalde Children’s Hospital in Buenos Aires, Argentina. She obtained a Specialist in Pharmaceutical Medicine degree from University of Basel, Switzerland and she is a Fellow of the Faculty of Pharmaceutical Medicine in London, UK (FFPM).
Follow Andrea Spezzi:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Zhangming Niu
Founder & CEO of MindRank AI
Follow Zhangming Niu:
About MindRank AI: MindRank is a developer of an AI-enabled drug-discovery platform intended to discover and develop next generation precision medicines.
James Field
CEO & Founder of LabGenius
James is founder and CEO of LabGenius. James completed his PhD studies at Imperial College London where his research was focused on re-engineering protein nanocages for biotechnological applications. Prior to his PhD, James completed a BSc in Biology with Microbiology and an MRes in Systems and Synthetic Biology, at Imperial College London. James is an active member of the synthetic biology community having participated in the iGEM competition both as an undergraduate (2009), advisor (2011) and judge (2016). In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact. James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).
Follow James Field:
About LabGenius: LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.
Ed McDermott
Co-Founder and Managing Director, UK of EMMAC Life Sciences
Ed McDermott is the co-founder and managing director at EMMAC Life Sciences.
Follow Ed McDermott:
About EMMAC Life Sciences: EMMAC is a medical cannabis company that works to join together the latest science and research with cutting-edge cultivation.
Dhivya Venkat
Co-Founder & Chief Executive Officer of Esya
Dhivya Venkat is the Co-Founder & Chief Executive Officer of Esya. University of Cambridge Degree NameGeneral ManagementField Of StudySuccessful Negotiation Strategies Dates attended or expected graduation2009
Follow Dhivya Venkat:
About Esya: Esya is a biotech company that measures, monitors, assist drug development, and pre-assess patient cohorts for treatment.
Keiran Olivares Whitaker
Founder & CEO of Entocycle
Environmental engineer, YC alumni, five years expertise in rearing insects, passionate environmentalist, deep sea diver.
Follow Keiran Olivares Whitaker:
About Entocycle: Entocycle’s automated insect farm produces environmentally friendly insect protein to feed farmed animals.
Susan Greenfield
Founder & CEO of Neuro-Bio
Follow Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Baroness Susan Greenfield
CEO & Founder of Neuro-Bio
Susan Greenfield is a neuroscientist, writer, and broadcaster. She has been awarded 30 Honorary Degrees from British and foreign universities and heads a multi-disciplinary research group exploring novel brain mechanisms linked to neurodegenerative diseases such Alzheimer’s and Parkinson’s. She is a Senior Research Fellow at Lincoln College, Oxford and has currently co-founded a biotech company developing a novel approach to neurodegenerative disorders (Neuro-Bio Ltd). In addition, she has published a neuroscientific theory of consciousness,’The Private Life of the Brain’ (2003) and developed a keen interest in the impact of modern technologies on how young people think and feel. This was discussed in her book, ‘ID: The Quest for Identity in the 21st Century’ (2008). In 1998 she received the Michael Faraday Medal from the Royal Society, was awarded a CBE in the Millennium New Year’s Honours List and was granted a non-political Life Peerage in 2001. In 2000 she was elected to an Honorary Fellowship of the Royal College of Physicians and in 2007 to an Honorary Fellowship of the Royal Society of Edinburgh. She was appointed Chancellor of Heriot Watt University in 2005. Further recognition of her work includes L’Ordre National de la Légion d’Honneur from the French Government, and the American Academy of Achievement Golden Plate Award, both received in 2003. Susan was also awarded the Australian Medical Research Society Medal in 2010. In 2011, Susan joined the Advisory Board of the Kusuma School of Biological Sciences at the Indian Institute for Technology, Delhi. In 2012, Susan was offered the Honorary Fellowship of the Institute of Risk Management and also became a Vice Patron of POWER International. Further on in 2012, Susan was selected to serve as the Parliamentary Patron of the Westminster Higher Education Forum, alongside of continuing to be a Parliamentary Patron of the Westminster Education Forum. Continuing through 2012, Susan bacame a Governor of The Florey Institute for Neuroscience and Mental Health and also started to suport the IAB (the International Advisory Board). In January 2014, she was included in the Debrett’s 500, “a recognition of the most influential and inspiring 500 people in Britain.”. Most recently, in July 2014, Susan was awarded as an Honorary Doctorate at Middlesex University.
Follow Baroness Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Alex Zhavoronkov
Founder & Chief Executive Officer of Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe’s largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Follow Alex Zhavoronkov:
About Deep Longevity, Insilico Medicine: Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Charles Sermon
General Counsel & Co-Founder of Mereo Biopharma
Charles is Mereo Biopharma’s General Counsel, Company Secretary and a co-founder. He has over 20 years’ experience in corporate law and biopharmaceuticals. He started his career as a corporate lawyer at Freshfields before joining Nomura as an Associate Director in 1998 where he worked for Nomura’s life science investment team investing globally in biotechnology companies. Charles was part of Phase4 Partners’ MBO from Nomura in 2010. Charles has an LLB (Hons) from Hull University. Charles is a Board Member of Phase4 Partners and a Member of the Mayor of London Enterprise Panel’s Digital Creative, Science and Technology Working Group. Prior to Nomura Charles was a corporate lawyer in London with Freshfields. Charles holds a LLB (Hons) from the University of Hull and a Diploma in Company Direction from the Institute of Directors.
Follow Charles Sermon:
About Mereo Biopharma: Mereo is a new UK-based speciality biopharmaceutical company.
Alastair MacKinnon
CMO and Co-Founder of Mereo Biopharma
Alastair joined the team in 2005. He serves as Board Observer for Albireo and Chroma. Further to these he has been actively involved in the investments in OncoMed (OMED), Proteolix and Nabriva. Prior to joining, Alastair was a practising physician, with a breadth of experience across cardiovascular and oncology surgery and intensive care. He holds a Physiology BSc (Hons) and MBBS from King’s College London, is a Member of the Royal College of Surgeons (Ed) and hold s a Diploma in Corporate Finance from the London Business School.
Follow Alastair MacKinnon:
About Mereo Biopharma: Mereo is a new UK-based speciality biopharmaceutical company.
Sam Cooper
Co-Founder of Phenomic AI
Sam Cooper, cofounder and CEO of Phenomic AI. Sam and his team use machine learning for automated image analysis to study cell biology and screen drugs. But that’s just the beginning.
Follow Sam Cooper:
About Phenomic AI: Phenomic AI is a developer of a drug discovery platform designed to discovery and optimize therapeutics directly against phenotypic assays.
Sergey Young
Founder of Longevity Vision Fund
Sergey Young is the Founder of Longevity Vision Fund.
Follow Sergey Young:
About Longevity Vision Fund, Peak State Ventures: Longevity Vision Fund invests in technologies that have the potential to disrupt life sciences and extend healthy lifespan.
Guido Franzoso
Scientific Founder of Kesios Therapeutics
Franzoso joined Imperial College London in June 2007 and is Head of the Centre for Cell Signalling and Inflammation and Professor and Chair of Signal transduction and Inflammation. He was previously at the University of Chicago for 10 years. Franzoso, is the principal founder of Kesios Therapeutics, a spin-out from Imperial College London founded in 2012. Franzoso’s work is highly regarded by the scientific community, as evidenced by numerous high-impact publications in journals, such as, Nature, Science, Cell, Immunity, Nature Cell Biology and Cancer Cell and he has been awarded substantial funding to pursue his research. Recognising the need to translate this research into healthcare benefit, Franzoso was able to raise £3.7M from the MRC for a multi-centre Phase I/IIa trial of DTP3 in multiple myeloma and he has also successfully achieved substantial project funding for both basic and clinical research from the MRC, CRUK and NIH (US). Franzoso owns several patents on intellectual property related to his research. Franzoso holds a medical degree from the University of Padua medical school, Italy and a Ph.D. in microbiological sciences from the Institute of Microbiology at the University of Padua.
Follow Guido Franzoso:
About Imperial College London, Kesios Therapeutics: Kesios Therapeutics, a London, UK-based oncology drug discovery company
Martin Murphy
Co-Founder & Chief Executive Officer of Syncona Partners LLP
Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 with The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of four Syncona companies: Achilles, Autolus, Blue Earth and OMass Therapeutics and continues to hold Board positions at these companies. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.
Follow Martin Murphy:
About Syncona Partners LLP: Syncona Partners LLP is a healthcare company focused on investing in and building global leaders in life science.
Vid Stojevic
Co-Founder and CEO of Kuano
Vid has spent the past 10 years working on string theory and tensorial methods in quantum physics and has held postdocs at UCL and the University of Vienna with pioneers in these fields. He has publications in numerous high impact journals.
Follow Vid Stojevic:
About Kuano: Kuano provides innovative quantum and AI solutions for drug discovery and design.
Johannes Solzbach
CEO & Co-Founder of Clustermarket
Johannes Solzbach has been Chief Executive Officer and Director at Clustermarket LTD.
Follow Johannes Solzbach:
About Clustermarket: One lab management platform that brings people, equipment and data together – no matter where they are.
Basil Omar
Founder & Chief Commercial Officer of CHAIN Biotechnology
Basil has a PhD in Physics from Loughborough University and MBA from Warwick Business School. He has held senior technical management roles in semiconductors, electronic displays and advanced materials with Philips Electronics and Sharp Corporation. Basil also has a background in Management Consultancy with PRTM (now PwC) and Grant Thornton, and has held senior business development and marketing roles at Transco/National Grid and Green Biologics. Basil via Woodbridge Innovation has supported numerous early stage companies in a range of high tech fields including clean energy and industrial biotech. Basil launched and ran the University of Gloucestershire’s business incubation hubs and is co-founder of the Gloucestershire Angel Investment Network. Basil is a farming and classic car enthusiast.
Follow Basil Omar:
About Bristol Business School, CHAIN Biotechnology: CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases.
Victor Dillard
Founder , COO & CEO of Desktop Genetics
A former chemical engineer keen on seeing personalized treatment realized, Victor has spent the past three years leading Desktop Genetics’ business development and CRISPR genome-editing initiatives. He has closed several partnerships with leading life science companies, placing Desktop Genetics at the forefront of CRISPR therapeutics research. Informed by his previous experience at P&G, GlaxoSmithKline, Flagship Ventures, Victor believes that software will be the key to unlocking the full potential of biotech R&D. He holds MEng, Chemical Engineering from Imperial College London and an MPhil in Bioscience Enterprise from the University of Cambridge.
Follow Victor Dillard:
About Desktop Genetics: Desktop Genetics is an international company to help researchers discover and treat the root genetic causes of human disease.
Sacha Carton
Co-Founder & COO of Airfinity
Sacha is co-founder & COO at Airfinity – a science information and analytics company. He is a data, tech and media entrepreneur who previously co-founded ad pepper media (FRA: APM), Adbrain (sold to NSDQ: TTD), Scala Ventures and advisory firm Ogmenta and has been an investor, advisor and director in multiple media, data, adtech, PE and M&A companies in Europe and the US.
Follow Sacha Carton:
About Airfinity, Scala Ventures: Airfinity is a science information and analytics company
Julian Melchiorri
Founder and CEO of Arborea
Julian Melchiorri is an inventor, engineer, and entrepreneur recognized by Forbes as a leading EU social entrepreneur under 30 years of age. Julian is the Founder and CEO of Arborea, a food-tech start-up that applies break-through proprietary biological and chemical engineering technology platforms to produce healthy food ingredients at low-cost and massive scale to help food producers build a food system where everyone eats well. Earlier in his career, Melchiorri designed and engineered both products and manufacturing processes for major Italian lighting production company and for the London high-tech collective ‘’Random International’’, making technology-driven interactive experiments and large scale installations, utilizing a multitude of technologies such as robotic, sensing and hydraulic technologies.
Follow Julian Melchiorri:
About Arborea: Arborea is industrialising photosynthesis to expand the world’s food supply
Pravin Badhe
Founder & CEO of SwaLife Biotech
Pravin Badhe has over 12 years of experience in Pharmaceutical field. He has expertise in target discovery and lead identification and has experience in drug repurposing in rare disease such as progeria. He is a Pharmacist and has PhD in life science. In PhD he has discover five novel small molecules from plants. He is an experience scientist and has got expertise in pharma wholesale, retail sales, marketing and general management. He has held number of positions with both research and development. As research assistant, he led cross-functional teams in the delivery of standardise plant extracts and fractions for cosmetic purpose. He is founder and CEO of Swalife Biotech and is responsible for developing and managing financial systems and policies. He is responsible in recruiting, communicating values and developing education opportunities. He will represent the company in strategic meetings and will be responsible for preparing financial reports, budgets, and financial statements for the organization. He is advisor in Shree Om Medico pharma distributor company in India. He brings extensive experience of growing organisations across all aspects of the biotech environment.
Follow Pravin Badhe:
About SwaLife Biotech: SwaLife Biotech discovers small molecules from plants for cosmetics and synthesizes novel anticancer plant alkaloids.
Ferdinando Randisi
Co Founder & CTO of FabricNano
Follow Ferdinando Randisi:
About FabricNano: FabricNano is a cell-free biomanufacturing company that develops a DNA-based flow reactor to unlock the future of biochemistry.
Grant Aarons
Co-Founder & CEO of FabricNano
Follow Grant Aarons:
About FabricNano: FabricNano is a cell-free biomanufacturing company that develops a DNA-based flow reactor to unlock the future of biochemistry.
Charlie Groome
Founder of Everna
Follow Charlie Groome:
About Everna: Everna is a biotech company developing novel therapeutics.
George Frodsham
Founder & CEO of MediSieve
George Frodsham founded MediSieve after being awarded his PhD in biochemical engineering from University College London (UCL), during which he developed the magnetic blood filter. As well as being a physicist and engineer, George is an entrepreneur. George was awarded a BBSRC Enterprise Fellowship from the Royal Society of Edinburgh in 2014. Since 1996, only 180 individuals have benefited from this highly competitive and prestigious programme. George has also completed the Entrepreneurship Summer School programme at the London Business School. This equipped him to research target markets and industries and turn his visions into viable businesses.
Follow George Frodsham:
About MediSieve: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Wayne Danter
Founder, President & CEO of Cotinga Pharmaceuticals
Dr. Wayne Danter is the President, Chief Executive Officer and a Director. Previously, he held the position of Chief Scientific Officer at COTI. Dr. Danter is the inventor of the CHEMSAS® process and one of the founders of COTI. He trained at the University of Western Ontario in Internal Medicine and Clinical Pharmacology. Prior to founding COTI, Dr. Danter was an Associate Professor of Medicine at the University of Western Ontario. His clinical focus, in addition to his teaching role, at the University was in General Cardiology, Cardiovascular Diseases associated with HIV a1d Cardiovascular Risk Management. Dr. Danter’s initial research focused on the medical application of Artificial Intelligence (AI) technologies to disease diagnosis and outcome prediction. The primary aspect of his research has focused on developing Hybrid AI models to pattern the relationship between molecular strudzure and biological activity. This research has resulted in a sophisticated process for decomposing complex molecules into critical elements that permit accurate molecular structure activity modeling (CHEMSAS). His research has been published in peer-reviewed publications and he has presented at numerous international meetings. Dr. Danter is a pioneer in the evolving interface between AI Technologies and pharmacotherapeutics. These AI technologies are anticipated to play a major role in 21st century drug development.
Follow Wayne Danter:
About Cotinga Pharmaceuticals: Cotinga Pharmaceuticals discovers and develops drug therapies for diseases.
Sergio Quezada
Founder of Achilles Therapeutics
Sergio Quezada is a Professorial Research Fellow and a Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory at University College London Cancer Institute. He is an expert in basic and translational research relating to cancer immunology with a focus on T cell immunobiology, immune-regulation, and the interplay between cancerous and immune cells within the tumour microenvironment. He has made seminal contributions to the understanding of the mechanisms underpinning the in vivo activity of checkpoint inhibitors (CPIs), particularly on the mechanisms of action of anti-CTLA-4 antibodies. Sergio has been the recipient of Dartmouth’s John W. Strohbern Medal for excellence in biomedical research, a CRUK Career Development Fellowship and the Cancer Research Institute investigator Award. Most recently he was awarded with a Cancer Research UK Senior Cancer Research Fellowship. Sergio holds a Ph.D. from Dartmouth Medical School. From 2004 to 2010 he held a post-doctoral position in the laboratory of Dr. James Allison at Memorial Sloan-Kettering Cancer Center.
Follow Sergio Quezada:
About Achilles Therapeutics, Achilles Therapeutics, UCL Cancer Institute: Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Javier Gonzalez-Zabaleta
Founder & CEO of Medimsight
Javier Gonzalez-Zabaleta was the main designer of the cloud model to bring worldwide medical imaging artificial intelligence solutions accessible to everyone. As one of the pioneers in this space, he has achieved a good experience in both market space and the technology. During last 10 years, he focused at the same time in business development, including direct communication with clinicians, and the understanding of the clinical trials market. Always open to talk, partnering and sharing knowledge. At the university, he studied computer science before made a master degree in computer vision making research in areas like multiple sclerosis and Alzheimer disease. Following his dream, empowering researchers and building super doctors, he has lived in Ponferrada, Madrid and now in London.
Follow Javier Gonzalez-Zabaleta:
About FundRx, Medimsight: Medical image triage and biomarkers analysis for precision medicine.
Raj Mehta
Co-Founder & CEO of Adendra Therapeutics
Follow Raj Mehta:
About Adendra Therapeutics, Apple Tree Partners: Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.
Caetano Reis e Sousa
Co-Founder of Adendra Therapeutics
Follow Caetano Reis e Sousa:
About Adendra Therapeutics: Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.
Anna Perdrix Rosell
Co-Founder & Co-CEO of Sixfold Bioscience
Anna Perdrix Rosell is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow Anna Perdrix Rosell:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
Karim Chine
Founder of RosettaHUB
Karim Chine is a London-based software architect and entrepreneur and the author and designer of RosettaHUB. Previously, he held positions within academic research laboratories and industrial R&D departments, including Imperial College London, EBI, IBM, and Schlumberger. Karim’s interests include large-scale distributed software design, cloud computing applications in research and education, open source software ecosystems, and open science. Since 2009, he has collaborated with the European Commission as an independent expert for the research e-infrastructure program and for the future and emerging technologies program. He has also served as an evaluator and a reviewer of many of EU’s flagship projects related to grids, desktop grids, scientific clouds, and science gateways. Karim holds degrees from Ecole Polytechnique and Telecom ParisTech.
Follow Karim Chine:
About RosettaHUB: rosettaHUB is a startup conducting research and development and targeting the building of the next generation of data science platforms.
Neel Patel
Founder & Chief Executive Officer of ZiO Health
Follow Neel Patel:
About ZiO Health: ZiO Health has developed proprietary pocket-sized technology, bringing lab testing to the point of use.
Sophia Karagiannis
Scientific Founder of Epsilogen
Sophia is a Reader in translational cancer immunology at KCL and a globally-recognised expert on the use of IgE antibodies to fight cancer. She co-founded and Chairs the Task Force on AllergoOncology and her group collaborates closely with the CRUK Centre for Drug Development. She holds a PhD from King’s College London.
Follow Sophia Karagiannis:
About Epsilogen: Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
Duncan Hall
Founder and CEO of Triumph Research Intelligence
Duncan has over fifteen years of consultancy experience, thirteen of which have been within clinical R&D in both CRO and Pharma businesses. Duncan started Triumph in 2002 with the aim of building a global business which would be focused in improving the delivery, quality and value of clinical systems. Duncan now takes a primarily strategic role in TRI, but still performs client delivery roles where possible.
Follow Duncan Hall:
About Triumph Research Intelligence: Triumph Research Intelligence is a risk-Based Monitoring Company.
Malcolm Weir
Founder & CEO of Heptares Therapeutics
Former Visiting Professor of Biochemistry at Imperial College, London. Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.) Former CEO of Inpharmatica Ltd.（present Galapagos NV). Founder and CEO of Heptares Therapeutics Ltd.
Follow Malcolm Weir:
About Heptares Therapeutics, Sosei Group: Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Cameron Shaw
Founder and COO of Virax Biolabs
Cameron Shaw is the founder and Chief Operations Officer at Virax Biolabs.
Follow Cameron Shaw:
About Virax Biolabs: Virax Biolabs is an innovative Biotechnology company focused on the prevention, detection and diagnosis of viral diseases
Brendon Noble
Founder of Regenerys
A medical charity funding the development of the next generation of stem cell related therapies. This ground breaking work is our passion and the therapies that will result from the work will change medicine and clinical outcomes for millions of patients. Follow @ukscf on Twitter
Follow Brendon Noble:
About Regenerys: Regenerys develops and sells regenerative medicine products in the streams requiring bioprocessing and biostorage.
Vincenzo Cerundolo
Founder of iOx Therapeutics Ltd.
Professor Cerundolo is Professor of Immunology at the University of Oxford and Director of the MRC Human Immunology Unit at the Weatherall Institute of Molecular Medicine. He was the first to show the mechanism of ligand binding of lipids to CD1d molecules and their subsequent presentation to lymphocytes. In addition, He was able to demonstrate the importance of iNKT cells in enhancing antigen specific T and B cell responses and their ability to abolish the immuno-suppressive activity of myeloid derived suppressor cells. This work led to the development of the engineered iNKT agonists being developed by iOx as potential immunotherapy candidates. He discovered the technology that is the basis for iOx Therapeutics and acts as scientific advisor to iOx.
Follow Vincenzo Cerundolo:
About iOx Therapeutics Ltd.: iOx Therapeutics Ltd. operates as an immuno-oncology company.
Mark Lowdell
CSO, Founder & CMO of INmuneBIO
CSO INmuneBio Inc.
Follow Mark Lowdell:
About Achilles Therapeutics, INmuneBIO, The Royal Free: INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.
Charles Ball
Co-Founder and Commercial Manager of Chronomics
Charles Ball is the Co-Founder and Commercial Manager at Chronomics.
Follow Charles Ball:
About Chronomics: Tech-bio company, providing access to a ‘bio-infrastructure’ to simplify and speed-up the use of biomarkers to improve everyday decisions.
Toby Call
Co-Founder of Chronomics
Toby Call is the Co-Founder of Chronomics.
Follow Toby Call:
About Chronomics: Tech-bio company, providing access to a ‘bio-infrastructure’ to simplify and speed-up the use of biomarkers to improve everyday decisions.
Daniel Elías Martín Herranz
Co-Founder and CSO of Chronomics
Daniel Elías Martín Herranz is the Co-Founder and CSO at Chronomics.
Follow Daniel Elías Martín Herranz:
About Chronomics: Tech-bio company, providing access to a ‘bio-infrastructure’ to simplify and speed-up the use of biomarkers to improve everyday decisions.
Michael O’Neill
Co-Founder and Director R&D of Inflection Biosciences
Michael O’Neill has more than 20 years’ experience working in the pharmaceutical industry. He was a Senior Research Scientist and Portfolio Manager at Eli Lilly for much of this time where he was responsible for developing project plans for the selection of projects and for their progression from discovery through to important development milestones. He established his own consulting business, Eolas, to help early stage companies to organize their research along commercial lines, becoming accomplished at building highly streamlined development plans. He has built consortia of commercial and academic groups to apply for major EU grants. Previously Dr. O’Neill was Head of Laboratory at Almirall and a Research Neuroscientist at Merck. He has authored over 80 papers, book chapters, patents and abstracts and is Honorary Visiting Senior Lecturer at the Science Policy Research Unit at the University of Sussex. He holds a BA Psychology from UCC and a PhD from QUB Belfast.
Follow Michael O’Neill:
About Inflection Biosciences: Inflection Biosciences is a company that develops small-molecule therapeutics for the treatment of cancer.
David Lane
COO and Co-Founder of EProfiler Solutions
Follow David Lane:
About EProfiler Solutions: EProfiler Solutions develops technology solutions to diagnose diseases.
Davidson Ateh
Co-Founder & CEO of BioMoti
Davidson is an entrepreneur operating in the life sciences. He has an interdisciplinary scientific background in bioengineering and was a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship. Davidson has significant technology translation experience including proof-of-concept studies, IP protection, non-dilutive grant applications, partnering, licensing and raising investment. He has won awards for his scientific and commercial activities. Davidson is a co-inventor of the Oncojan™ drug delivery platform, co-founder of BioMoti and leads product and business development activities.
Follow Davidson Ateh:
About BioMoti: BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells
Andy Gardiner
Co-Founder of Sundew
Andy Gardiner currently works as the Co-Founder for Sundew ApS.
Follow Andy Gardiner:
About Sundew: Sundew is a biotechnology company that provides biological services for the treatment of aquatic pests and diseases.
Philipp Boeing
Co-Founder of Bento lab
Philipp Böing is a Co-Founder at Bento Lab.
Follow Philipp Boeing:
About Bento lab: Bento·lab is a powerful, personal laboratory that enables scientists, artists.
Bethan Wolfenden
Co-Founder of Bento lab
Follow Bethan Wolfenden:
About Bento lab: Bento·lab is a powerful, personal laboratory that enables scientists, artists.
Jeff Moore
Founder & CEO of Curileum Discovery Ltd
Follow Jeff Moore:
About Curileum Discovery Ltd: Curileum Discovery Ltd is a drug target discovery company in London targeting defective stem cells underpinning serious GI diseases
Charles Large
Founder and CEO of Autifony Therapeutics
Charles Large received his first degree and PhD from the University of Bristol and has more than 20 years of experience of drug discovery and development in the pharmaceutical industry. Before founding Autifony, he was Director of Molecular and Cellular Biology within the Neuroscience Centre of Excellence for Drug Discovery at GlaxoSmithKline, and has worked on programs focused on schizophrenia, Alzheimer’s disease, epilepsy, bipolar disorder, and major depression. He is an expert on drugs that modulate voltage gated ion channels and their application to neurological and psychiatric disorders. He has built up a reputation in the field of sodium channel blocking drugs, and has collaborated widely with academic groups. He has authored over 50 papers, book chapters and patents relating to ion channel modulators.
Follow Charles Large:
About Autifony Therapeutics: Autifony Therapeutics is a biotechnology company developing medicines to treat hearing disorders such as hearing loss and tinnitus.
Adrian Hayday
Co-Founder of GammaDelta Therapeutics
Adrian Hayday was trained in biochemistry at Cambridge, and obtained a PhD in molecular virology from London University. He began studying immunology in 1982 at MIT, where he and his colleagues first described the wholly unanticipated T cell receptor gamma chain genes. Since then Professor Hayday has used many parameters to establish that gamma-delta T cells are clearly distinct from conventional T cells. Those parameters include the cells’ responses to different products of a novel gene family expressed at body surfaces, that Professor Hayday and his colleagues identified. He showed that this unique biology allows gamma-delta T cells to make rapid responses to tissue dysreguation, rather than to specific pathogens, and thereby to monitor tissue integrity. This may explain Professor Hayday’s observation that gamma-delta T cell deficiency is associated with a profound susceptibility to skin carcinogens, findings which were instrumental in promoting his and others’ interest in the cells’ clinical application. In other clinical activities, he directed a team describing the human immune response to vaccination and described the unique properties of human autoantibodies. Additionally, he is the lead-investigator of a Wellcome Trust-supported, multi-centre, high-throughput phenotyping screen identifying novel genetic regulators of the immune system. Professor Hayday has authored over 200 papers, of which he is first, last, or corresponding author on over 120, and of which 150 are original research contributions. He has received many awards, including the William Clyde deVaneMedal, Yale College’s highest honour for scholarship and teaching, an honorary fellowship of King’s College London, and the King’s College Business Award, 2008. He was elected to lead the British Society of Immunology (2005-09) and has organized many scientific meetings including the 2014 Gordon Conference in Immunochemistry and Immunobiology, and the scientific programme for the 2012 European Congress of Immunology. He is an elected fellow of the Academy of Medical Sciences and of the Royal Society. He has formally advised many institutions including Institut Pasteur; the Max Planck Institute; Kyoto University, the Wellcome Trust, and Cancer Research UK, whose science committee he chaired for three years. He has participated in many aspects of the biotech/pharmaceutical sector, including membership of the MedImmune SAB, and was a co-founder of ImmunoQure AG before co-founding GammaDelta Therapeutics in 2016.
Follow Adrian Hayday:
About GammaDelta Therapeutics: GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells
STEVE HOLMES
CEO and Founder of Capella BioScience
Follow STEVE HOLMES:
About Capella BioScience: Capella Bioscience engages in the discovery and development of monoclonal antibodies.
Rafael Michaeli
CoFounder of SAVA
Follow Rafael Michaeli:
About SAVA: The first effortless continuous molecular tracker unlocking human perfomance
Michael Larsson
Founder of Polysense
PhD
Follow Michael Larsson:
About Polysense: Polysense develops sensors and systems for medical and industrial applications
Joanne Taylor
Founder of Life Science Leaders
Follow Joanne Taylor:
About Life Science Leaders: Life Science Leaders is an executive search company that specializes in the life science and medical industries.
Jan Berghe
Managing Director & Co-Founder of Novalis Biotechnology Incubation
Follow Jan Berghe:
About Novalis Biotechnology Incubation: Novalis Biotech Incubation is an early-stage vc fund that invests in biotechnology and life sciences related companies.
Julie Barnes
Founder/ Chief Scientific Officer & Chief Executive Officer of Abcodia
Julie has over 20 years experience of the Pharmaceutical and Biotechnology industry, including 15 years experience of early R&D with GlaxoSmithKline. More recently Julie was director and Chief Scientific Officer at BioWisdom, a healthcare technology company. Her mix of scientific and commercial experience in large pharmaceutical and small start-ups and academic network brings a strong understanding of what is required to successfully lead Abcodia as an ethical and collaborative organisation.
Follow Julie Barnes:
About Abcodia: Abcodia is an innovative biotech company engaged in the validation and discovery of molecular biomarkers.
Yen Choo
Founder of Plasticell
Yen Choo is a Founder at Plasticell.
Follow Yen Choo:
About Plasticell: Plasticell offers a cell-based screening technology for the discovery of small molecule drugs that regenerate cells of the body.
Ifeyinwa Kanu
Founder and CEO of IntelliDigest
Follow Ifeyinwa Kanu:
About IntelliDigest: IntelliDigest is a biotechnology start-up company from Heriot Watt University and part of the Climate KIC Accelerator Program.
Jorge Cortell
Founder and CEO of Kanteron Systems
Follow Jorge Cortell:
About Kanteron Systems: Transforming patient care through the combination of medical imaging and clinical genomics
Andrew Hook
Founder & CEO of Tracepad
Follow Andrew Hook:
About Tracepad: Tracepad develops innovative solutions for pharmaceutical provenance.
Daniel Ives
Founder of Mitohelix
Follow Daniel Ives:
About Mitohelix: UK-based biotech startup in stealth
Radha Desai
Founder of Mitohelix
Follow Radha Desai:
About Mitohelix: UK-based biotech startup in stealth
